An article in the Algarve Resident edition of November 6, entitled ‘Portuguese drug taking on the world’, contained incorrect information about the medicine Zebinix®.
The article said: “A drug which treats epilepsy, pain and depression which has been solely developed in Portugal has come onto the European market.”; “But the drug can also be used to treat neuropathy pain and some psychiatric illnesses such as depression.”
In a statement, Grupo Bial, researchers and developers of the medicine, said: Zebinix®, which has been researched and developed by Grupo Bial, received authorisation from the European Commission in April 2009 to market the medicine for the adjuvant treatment of partial epilepsy seizures in adults, with or without secondary generalisation. The drug has not, as yet, received approval from the regulatory bodies to be used to treat any other ailments.
We are happy to set the record straight.